Fierce Biotech February 23, 2024
Once again, Insulet has broken its own records for annual revenue intake.
In its full-year earnings presentation Thursday afternoon, the diabetes devicemaker reported year-over-year growth of 30%, which sent its 2023 earnings to $1.7 billion, compared to the previous year’s $1.3 billion take.
As CEO Jim Hollingshead noted during the investor presentation, that increase represents Insulet’s “eighth consecutive year of 20-plus percent revenue growth” when calculated on a constant currency basis.
The growth was led largely by Insulet’s Omnipod 5 automated insulin delivery (AID) system, as 2023 marked its first full year of availability in both the U.S. and Europe after racking up regulatory clearances throughout 2022. According to Hollingshead, not only was Omnipod 5 responsible for $1 billion of...
Today's Sponsors
Today's Sponsor